Citigroup Increases ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $40.00Market Beat·2 days ago, 10:42 AMACAD+0.51%
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | ACAD Stock NewsStockTitan·Aug 23 at 06:01 PMACAD+0.51%
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACADMarket Beat·Aug 17 at 04:36 AMACAD+0.51%
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACADrttnews·Aug 13 at 03:30 AMANRO-0.63%ACAD+0.51%
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s DataMarket Beat·Aug 12 at 02:04 PMACAD+0.51%
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advanceQuartr·Aug 12 at 01:41 PMACAD+0.51%
Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) StockMarket Beat·Aug 7 at 06:08 PMACAD+0.51%
Acadia Pharmaceuticals CFO Mark C. Schneyer disposes of 25,141 common shares worth $730,047.52PUBT·Aug 7 at 05:00 PMACAD+0.51%
Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)Tip Ranks·Aug 5 at 03:25 PMACAD+0.51%
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Citizens Jmp Analyst SaysMarket Beat·Aug 5 at 10:24 AMACAD+0.51%
Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)Tip Ranks·Aug 4 at 10:35 PMACAD+0.51%
Acadia Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 307.96 MEarnings Watch·Aug 4 at 03:56 PMACAD+0.51%
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results | ACAD Stock NewsStockTitan·Aug 4 at 07:05 AMACAD+0.51%
10:31 ETDementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsightprnewswire·Aug 3 at 09:31 AMBMY-0.92%ACAD+0.51%
The Manufacturers Life Insurance Company Raises Stock Holdings in ACADIA Pharmaceuticals Inc. $ACADMarket Beat·Aug 3 at 04:12 AMACAD+0.51%UBS-0.29%
